The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure

Canadian Journal of Cardiology

Volumn 29, Issue 2, 2013, Pages 168-181

  McKelvie, Robert S ^a   Moe, Gordon W ^b   Ezekowitz, Justin A ^c   Heckman, George A ^a,d   Costigan, Jeannine ^e   Ducharme, Anique ^f   Estrella Holder, Estrellita ^g   Giannetti, Nadia ^h   Grzeslo, Adam ^a,i   Harkness, Karen ^a   Howlett, Jonathan G ^j   Kouz, Simon ^k   Leblanc, Kori ^l   Mann, Elizabeth ^m   Nigam, Anil ^f   O'Meara, Eileen ^f   Rajda, Miroslaw ^m   Steinhart, Brian ^b   Swiggum, Elizabeth ⁿ   Le, Vy Van ^f   Zieroth, Shelley ^g   Arnold, J Malcolm O ^o   Ashton, Tom ^p   D'Astous, Michel ^q   Dorian, Paul ^l   Haddad, Haissam ^r   Isaac, Debra L ^j   Leblanc, Marie Hélène ^s   Liu, Peter ⁱ   Rao, Vivek ⁱ   Ross, Heather J ⁱ   Sussex, Bruce ^t   more..

^a MCMASTER UNIVERSITY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF WATERLOO   (Canada)

^e St Mary's General Hospital   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g ST BONIFACE GENERAL HOSPITAL   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ Joseph Brant Memorial Hospital Burlington   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k UNIVERSITÉ LAVAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m DALHOUSIE UNIVERSITY   (Canada)

ⁿ ROYAL JUBILEE HOSPITAL   (Canada)

^o UNIVERSITY OF WESTERN ONTARIO   (Canada)

^p Penticton   (Canada)

^q UNIVERSITÉ DE MONCTON   (Canada)

^r UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^s LAVAL UNIVERSITY   (Canada)

^t Health Sciences Centre St John's   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; BUCINDOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LOOP DIURETIC AGENT; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MILRINONE; MINERALOCORTICOID ANTAGONIST; MORPHINE; NESIRITIDE; NITRIC ACID; NORADRENALIN; PHENYLEPHRINE; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CHEMISTRY; CANADA; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DIURETIC THERAPY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ELECTROCARDIOGRAM; ENDOTRACHEAL INTUBATION; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART EDEMA; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE REDUCED EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; LABORATORY TEST; LOW DRUG DOSE; MEDICAL PRACTICE; MEDICAL SOCIETY; MORTALITY; NONINVASIVE VENTILATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PATIENT CARE; PATIENT MONITORING; PHYSICAL EXAMINATION; PHYSICIAN; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK FACTOR; SYMPTOM; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS CONGESTION;

CANADA; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84872688367     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.10.007     Document Type: Article

References (112)

1. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336:924-926.
2. McCormack J.P., Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician 2007, 53:1326-1327.
3. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216.
4. Arnold J.M., Liu P., Demers C., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006, 22:23-45.
5. Arnold J.M., Howlett J.G., Dorian P., et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007, 23:21-45.
6. Nohria A., Tsang S.W., Fang J.C., et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003, 41:1797-1804.
7. Kociol R.D., Pang P.S., Gheorghiade M., Fonarow G.C., O'Connor C.M., Felker G.M. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol 2010, 56:1071-1078.
8. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
9. Moe G.W. BNP in the diagnosis and risk stratification of heart failure. Heart Fail Monit 2005, 4:116-122.
10. Moe G.W., Howlett J., Januzzi J.L., Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007, 115:3103-3110.
11. Baggish A.L., Siebert U., Lainchbury J.G., et al. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am Heart J 2006, 151:48-54.
12. Steinhart B., Thorpe K.E., Bayoumi A.M., Moe G., Januzzi J.L., Mazer C.D. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009, 54:1515-1521.
13. Park J.H., Balmain S., Berry C., Morton J.J., McMurray J.J. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. Heart 2010, 96:533-538.
14. Gray A., Goodacre S., Newby D.E., Masson M., Sampson F., Nicholl J. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008, 359:142-151.
15. Gray A., Goodacre S., Seah M., Tilley S. Diuretic, opiate and nitrate use in severe acidotic acute cardiogenic pulmonary oedema: analysis from the 3CPO trial. QJM 2010, 103:573-581.
16. Peacock W.F., Hollander J.E., Diercks D.B., Lopatin M., Fonarow G., Emerman C.L. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J 2008, 25:205-209.
17. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011, 364:797-805.
18. Brater D.C. Diuretic therapy. N Engl J Med 1998, 339:387-395.
19. Wilson J.R., Reichek N., Dunkman W.B., Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981, 70:234-239.
20. Gardtman M., Waagstein L., Karlsson T., Herlitz J. Has an intensified treatment in the ambulance of patients with acute severe left heart failure improved the outcome?. Eur J Emerg Med 2000, 7:15-24.
21. Ducharme A., Doyon O., White M., Rouleau J.L., Brophy J.M. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ 2005, 173:40-45.
22. Kiyingi A., Field M.J., Pawsey C.C., Yiannikas J., Lawrence J.R., Arter W.J. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990, 335:29-31.
23. van Vliet A.A., Donker A.J., Nauta J.J., Verheugt F.W. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993, 71:21A-28A.
24. Cotter G., Metzkor E., Kaluski E., et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998, 351:389-393.
25. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002, 287:1531-1540. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF), [erratum in 2002;288:577].
26. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011, 365:32-43.
27. Mullens W., Abrahams Z., Francis G.S., et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008, 52:200-207.
28. Cleland J.G., Freemantle N., Coletta A.P., Clark A.L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006, 8:105-110.
29. Cuffe M.S., Califf R.M., Adams K.F., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
30. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003, 41:997-1003.
31. Ezekowitz J.A., Bakal J.A., Kaul P., Westerhout C.M., Armstrong P.W. Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail 2008, 10:308-314.
32. Jondeau G., Neuder Y., Eicher J.C., et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009, 30:2186-2192.
33. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007, 49:675-683.
34. Bart B.A., Goldsmith S.R., Lee K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012, 367:2296-2304.
35. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
36. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
37. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007, 297:1319-1331.
38. Cecconi M., Reynolds T.E., Al-Subaie N., Rhodes A. Haemodynamic monitoring in acute heart failure. Heart Fail Rev 2007, 12:105-111.
39. Marik P.E. Pulmonary artery catheterization and esophageal doppler monitoring in the ICU. Chest 1999, 116:1085-1091.
40. Lee D.S., Schull M.J., Alter D.A., et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail 2010, 3:228-235.
41. Kelder J.C., Cramer M.J., van W.J., et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011, 124:2865-2873.
42. Mant J., Doust J., Roalfe A., et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009, 13:1-207. iii.
43. Owan T.E., Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005, 47:320-332.
44. Hildebrandt P., Collinson P.O., Doughty R.N., et al. Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur Heart J 2010, 31:1881-1889.
45. Kirkpatrick J.N., Vannan M.A., Narula J., Lang R.M. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol 2007, 50:381-396.
46. Rudski L.G., Lai W.W., Afilalo J., et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010, 23:685-713.
47. Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization. Eur Heart J 2010, 31:2501-2555.
48. Schwitter J., Arai A.E. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. Eur Heart J 2011, 32:799-809.
49. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 1994, The Criteria Committee of the New York Heart Association, Little, Brown, Boston. 9th Ed.
50. Hogg K., Swedberg K., McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004, 43:317-327.
51. Vasan R.S., Benjamin E.J., Levy D. Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996, 156:146-157.
52. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2011, 33:1750-1757. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC).
53. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
54. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
55. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
56. Hogg K., McMurray J. The treatment of heart failure with preserved ejection fraction ("diastolic heart failure"). Heart Fail Rev 2006, 11:141-146.
57. Hung M.J., Cherng W.J., Kuo L.T., Wang C.H. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002, 56:57-62.
58. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
59. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
60. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
61. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
62. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
63. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
64. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
65. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
66. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
67. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
68. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
69. McMurray J., Cohen-Solal A., Dietz R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005, 7:710-721.
70. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
71. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007.
72. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
73. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
74. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001, 344:1659-1667. Beta-Blocker Evaluation of Survival Trial Investigators.
75. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003, 289:712-718.
76. Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002, 82:149-158.
77. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336:525-533.
78. Hood W.B., Dans A.L., Guyatt G.H., Jaeschke R., McMurray J.J. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004, 10:155-164.
79. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
80. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
81. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
82. Fox K., Ford I., Steg P.G., Tendera M., Robertson M., Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008, 372:817-821.
83. Swedberg K., Komajda M., Bohm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885.
84. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148:157-164.
85. Homma S., Thompson J.L., Pullicino P.M., et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012, 366:1859-1869.
86. Amabile C.M., Spencer A.P. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004, 164:709-720.
87. Feenstra J., Grobbee D.E., Remme W.J., Stricker B.H. Drug-induced heart failure. J Am Coll Cardiol 1999, 33:1152-1162.
88. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751-1756.
89. Howlett J.G., McKelvie R.S., Arnold J.M., et al. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol 2009, 25:85-105.
90. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005, 352:225-237.
91. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996, 335:1933-1940.
92. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351:2481-2488.
93. Steinbeck G., Andresen D., Seidl K., et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009, 361:1427-1436.
94. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004, 350:2140-2150.
95. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
96. Dupont M., Rickard J., Baranowski B., et al. Differential echocardiographic response to cardiac resynchronization therapy and clinical outcomes according to QRS morphology and QRS duration. J Am Coll Cardiol 2012, 60:592-598.
97. Hsu J.C., Solomon S.D., Bourgoun M., et al. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) study. J Am Coll Cardiol 2012, 59:2366-2373.
98. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009, 361:1329-1338.
99. Sipahi I., Carrigan T.P., Rowland D.Y., Stambler B.S., Fang J.C. Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Arch Intern Med 2011, 171:1454-1462.
100. Sipahi I., Chou J.C., Hyden M., Rowland D.Y., Simon D.I., Fang J.C. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am Heart J 2012, 163:260-267.
101. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010, 363:2385-2395.
102. Healey J.S., Hohnloser S.H., Derek V., et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the resynchronization for ambulatory heart failure trial (RAFT). Circ Heart Fail 2012, 5:566-570.
103. Mamas M.A., Caldwell J.C., Chacko S., Garratt C.J., Fath-Ordoubadi F., Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009, 11:676-683.
104. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983-988.
105. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
106. Gillis A.M., Verma A., Talajic M., Nattel S., Dorian P. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011, 27:47-59.
107. Fauchier L., Grimard C., Pierre B., et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009, 103:248-254.
108. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010, 31:2369-2429.
109. Khand A.U., Rankin A.C., Martin W., Taylor J., Gemmell I., Cleland J.G. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol 2003, 42:1944-1951.
110. Roy D., Talajic M., Nattel S., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
111. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998, 98:2574-2579.
112. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678-2687.